SummaryDengue virus (DENV) and Zika virus (ZIKV) are rapidly emerging mosquito-borne flaviviruses that represent a public health concern. Understanding host protective immunity to these viruses is critical for the design of optimal vaccines. Over a decade of research has highlighted a significant contribution of the T-cell response to both protection and/or disease enhancement during DENV infection, the latter being mainly associated with sub-optimal cross-reactive T-cell responses during secondary infections. Phase IIb/III clinical trials of the first licensed tetravalent dengue vaccine highlight increased vaccine efficacy in dengue-immune as opposed to dengue-naive vaccinees, suggesting a possible immunoprotective role of pre-existing DENV-specific T cells that are boosted upon vaccination. No vaccine is available for ZIKV and little is known about the T-cell response to this virus. ZIKV and DENV are closely related viruses with a sequence identity ranging from 44% and 56% for the structural proteins capsid and envelope to 68% for the more conserved non-structural proteins NS3/NS5, which represent the main targets of the CD4 + and CD8 + T-cell response to DENV, respectively. In this review we discuss our current knowledge of T-cell immunity to DENV and what it can teach us for the study of ZIKV. The extent of T-cell cross-reactivity towards ZIKV of pre-existing DENV-specific memory T cells and its potential impact on protective immunity and/or immunopathology will also be discussed.Keywords: T cells; memory; virus; human; cell trafficking DENV and ZIKV: similarities and differences
Dengue virus (DENV) and Zika virus (ZIKV) belong to the Flavivirus genus of the Flaviviridae family of viruses along with other arthropod-borne viruses that may have significant impact on human health such as Yellow fever virus (YFV), West Nile virus (WNV), Japanese encephalitis virus (JEV) and tick-borne encephalitis virus (TBEV).No specific antiviral therapeutic is available for these viruses and treatments are supportive in nature. Protective vaccines are available for JEV, TBEV and YFV and a partially protective vaccine has recently been licensed for DENV. 1 The live-attenuated YFV vaccine, which is safe and extremely effective, was shown to elicit long-lived neutralizing antibodies and a strong CD4 + and CD8 + Tcell response, 2,3 components that we believe are key to a successful vaccine. However, the co-circulation of DENV as four distinct serotypes (DENV 1-4) and the risk of immunopathology associated with sub-optimal cross-reactive B-cell and T-cell responses to heterologous serotypes represent critical factors for the development of a fully protective DENV vaccine.Dengue virus, ZIKV and the other flaviviruses are enveloped viruses with a 10Á7-kb positive-strand RNA genome encoding for a single polyprotein that is posttranslationally cleaved into three structural proteins (capsid, membrane, envelope) and seven non-structural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b, NS5). DENV 1-4 serotypes share approximately 70% amino ac...